N/A N=37 A Photoxicity and Photoallergy Study of a Developmental Face Cream, Serum and Lotion
Skin Care
Primary: Percentage of Participants With Photo-initiated Potential Sensitization Reaction — 0; 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=16 Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)
Idiopathic Solar Urticaria
Primary: Assessment of the Minimal Urticaria Dose (MUD) on Each Test Site, After Application of the Test Products — 4.33; 3.93; 3.80; 3.67 Photodermatosis Protection Factor
Phase 1 N=59 Clinical Evaluation of the Photoallergy Potential of Xenaderm Ointment
Healthy
Primary: Frequency Distribution of Skin Irritation Scores — 39; 10; 3; 0 Scores on a scale
Phase 1 N=72 Assessment of the Human Systemic Absorption of Sunscreen Ingredients
Systemic Exposure to Sunscreen Ingredients
Primary: Avobenzone Maximum Concentration — 1.8; 4.3; 4.0; 3.4 ng/mL
Phase 1 N=30 Assessing a Natural Product Plus Bioadhesive Nanoparticle (BNP) Sunscreen
Skin Cancer
Primary: DNA Damage Level by Cyclobutane Pyrimidine Dimer (CPD) Measurement — 2.48; 2.18; 2.64; 1.14 Optical Density Units — p=0.003
Phase 3 N=137 Study to Find Out if Cream V61-044 Used to Treat Fungal Infections Causes an Allergic Skin Reaction to Sunlight in Healthy Participants
Dermatitis, Photoallergic
Primary: Photoallergic Reaction Evaluation Reported as Number of Test Site With Different Erythema Score During Challenge Phase - All Treated Subjects — 325; 24; 343; 6 Test site
Phase 1 N=38 Clinical Evaluation of the Phototoxic Potential of Xenaderm Ointment
Healthy
Primary: Skin Reaction Score — 0.4; 0.5; 0.1; 0.4 units on a scale
N/A N=164 UV Exposure Assessed With Wearable Sensor and Sun Protection
Sunburn, Erythema · Sun Protection
Primary: Acceptability of Wearing UV Sensor and Receiving Text Messages — 22; 39.1; 40.1; 40.6 score on a scale — p=<0.01
N/A N=36 To Assess the Photosensitisation and Photoallergy Potential of a Cosmetic Facial Product in Healthy Participants
Skin Care
Primary: Combined Skin Irritation (Dermal Response) and Superficial Irritation (Other Effects) Scores at Induction Phase at Day 2 — 0; 0 Score on scale
N/A N=31 An Assessment of TLR4 and TOPK/PRPK Signaling in Sun Damaged Human Skin Acutely Exposed to Solar Simulated Light
Sun Damaged Skin
Primary: Number of TLR4 Signaling Pathway Analytes With a Significant Change in Expression From Baseline (Pre-solar Stimulated Light Exposure to 1 and 24 Hours Post Exposure)…
Phase 1 N=35 Evaluation of Potential Phototoxicity Skin Reaction After Use of MC2-01 Cream
Phototoxicity
Primary: Within-subject Comparison and Evaluator Rating of Possible Dermal Reactions (Erythema, Edema and Other Signs of Cutaneous Irritation), After Application of MC2-01 Cream…
Phase 4 N=128 Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test
Skin Irritation
Primary: Area of Erythema and Elevated Responses of Skin to Product — 91; 68; 33; 42 participants
N/A N=40 Potential Impact of Patient Vitamin D Status in AK Response to MAL-PDT
Actinic Keratosis
Primary: Changes From Baseline in Actinic Keratosis - Lesion Base Count. — 1.15; 2.65; 1.15; 2.60 lesions — p=<0.001
Phase 3 N=32 Study to Learn More About the Potential of Antifungal Cream V61-044 Containing Trolamine to Cause Irritant Reaction of the Skin to Ultra Violet Light in Healthy Human Subjects
Dermatitis, Phototoxic
Primary: Phototoxic Reaction Evaluation Reported as Number of Test Site With Different Erythema Score — 77; 10; 85; 2 Test site
Phase 1 N=259 Contact Sensitization Potential of 828 Ointment
Healthy Volunteers
Primary: Number of Participants That Exhibited a Score Less Than 1.5 on the Jordan-King Scale — 205 participants
Phase 2 N=10 Omalizumab in Severe and Refractory Solar Urticaria
Solar Urticaria
Primary: Proportion of Patients With Remission of Solar Urticaria Under Experimental Conditions (Phototesting) — 2 Participants
N/A N=41 Using Physical Tracking to Predict Sunburn
Prevention
Primary: Prevalence of Sun Protection Practices — 0.30; 0.43; 0.35; 0.41 proportion of practices/day
Phase 4 N=30 Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses
Actinic Keratosis
Primary: Percent Change in the Number of Actinic Keratoses — -75 % change in number of actinic keratoses
N/A N=31 Effectiveness of a Knowledge-based Intervention for Patients With Cutaneous Lupus Erythematosus
Cutaneous Lupus Erythematosus
Primary: Percentage of Subjects Who Correctly Answered a Knowledge Assessment Item Immediately Before and After an Educational Lecture — 52; 94; 19; 90 percentage of participants
Phase 1 N=7 Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus
Cutaneous Lupus
Primary: Change in Percentage of UVB-induced Apoptotic Epidermal Cells — 20.06; 3.03; -17.03 percentage of epidermal cells
Phase 1 N=85 Evaluation of Photosafety of BI 730357 Compared to Placebo and the Known Photosensitizing Agent Ciprofloxacin
Healthy
Primary: Photosensitivity Index at 24 Hours Under Condition 1 (i.e., Under Full Range of UVB/UVA Exposure, Simulating Midday Summer Outdoor Sun Exposure) — 0.93; 1.01; 1.00; 1.04…
N/A N=10 Solius UV Light Source in Improving Serum Levels of 25-hydroxyvitamin D
Vitamin D Deficiency · Vitamin D Insufficiency
Primary: Serum 25-hydroxyvitamin D — 25.4 ng/nl
Phase 1 N=34 A 4-Day Study to Evaluate the Photoxicity of Diacerein 1% Topical Ointment in Healthy Volunteers
Healthy
Primary: Observed Phototoxicity — 0.15; 0.15; 0.00; 0.00 Score on a scale — p=1.0000
N/A N=6 Low-dose UVA1 Radiation in Cutaneous Lupus Patients
Cutaneous Lupus Erythematosus
Primary: Change in Cutaneous Lupus Disease Area and Severity Index (CLASI) Activity Score — -1 Units on a scale
Phase 2 N=75 Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses
Actinic Keratosis
Primary: Clinical PDT Response as Measured by Percent Change in AK Lesions From Baseline to 3 Months — 59.1; 72.5 Percent change of AK lesions
N/A N=543 Virtual Sun Safe Workplaces Ph II (SSW Works)
Skin Cancer · Occupational Exposure
Primary: Change From Baseline Employee Sun Protection Practices at 1 Year — 3.55; 3.30; 3.71; 3.46 score on a scale
Phase 3 N=10 Determination of Sun Protection in Sunscreen Formulas (Study SR09-15)(P08236)(COMPLETED)
Sun Protection
Primary: Determination of Sunscreen Protection Factor (SPF) — 14.72; 15.00 Score on a scale
Phase 2 N=20 Photoactive Porphyrins (PAP) Levels After Topical Visonac Application in Acne Patients
Acne Vulgaris
Primary: Photoactive Porphyrins Level — 33.0; 24.8; 19.7 Fluorescence intensity unit
Phase 1 N=58 Evaluation of Potential Development of Photoallergic Skin Reaction After Use of MC2-01 Cream
Photoallergy
Primary: Within-subject Comparison of Dermal Reaction by the Overall Numeric Rating of Erythema and Edema at 5 Defined Test Sites, After Application of MC2-01 Cream, MC2-01…
N/A N=7 Photocil (Topical) for the Treatment of Atopic Dermatitis
Atopic Dermatitis
Primary: Number of Pruritus Events in Last 30 Days — 7.4; 1.9 Events